Spruce biosciences to present findings on retrospective analysis of completion rates for cah studies at pediatric endocrine society 2023 annual meeting

South san francisco, calif.--(business wire)--spruce biosciences, inc. (nasdaq: sprb), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that a submitted abstract was accepted for poster presentation at the pediatric endocrine society (pes) 2023 annual meeting taking place may 5-8, 2023, in san diego, calif. mitchell geffner, m.d., will present findings on a retrospective analysis of completion rates for adult and pediatric congenital adrenal hyperplasia (cah) studies. details are as follows: title: clinical trials in cah: so many starting, but not so many finishing abstract number: 6407 poster session: 3 session date & time: sunday, may 7, 2023 from 12:30 pm – 2 pm pt presenter: mitchell e. geffner, m.d., co-director of the congenital adrenal hyperplasia comprehensive care clinic and professor of pediatrics, keck school of medicine of university of southern california authors: p.j. ramtin, r. will charlton m.d., m.a.s., mitchell e. geffner m.d. access more information about pes 2023 here. about spruce biosciences spruce biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. spruce is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy for patients suffering from classic congenital adrenal hyperplasia (cah). spruce is also developing tildacerfont for women suffering from polycystic ovary syndrome (pcos) with primary adrenal androgen excess. to learn more, visit www.sprucebiosciences.com and follow us on twitter @spruce_bio, linkedin, facebook and youtube.
SPRB Ratings Summary
SPRB Quant Ranking